The FDA's Treatment IND Rule—A Glimpse into the Future of Drug Regulation in the US?

WD Appler - Food, Drug, Cosmetic Law Journal, 1988 - JSTOR
The Food and Drug Administration (FDA) has had some difficulty over the past two years in
navigating what Commissioner Frank E. Young has described as the" fine line that public …

FDA responds to institute of medicine drug safety recommendations—in part

BM Psaty, RA Charo - JAMA, 2007 - jamanetwork.com
Setting The FDA is an underfunded agency charged with regulating products that
collectively constitute nearly 25% of the US gross domestic product. 4 A century ago, the …

Looking Abroad: Clinical Drug Trials

CR Hathaway, JR Manthei, JB Haas, CA Scherer - Food & Drug LJ, 2008 - HeinOnline
To remain competitive, drug, device and biotechnology companies must continually pursue
innovative new products and product improvements. Clinical trials, which are essential to the …

FDA policy on unapproved drug products: past, present, and future

R Chhabra, ME Kremzner… - Annals of …, 2005 - journals.sagepub.com
OBJECTIVE To review the history of drug regulation by the Food and Drug Administration
(FDA) as it relates to unapproved drugs and FDA policy, along with the FDA's efforts to avoid …

Health options foreclosed: how the FDA denies Americans the benefits of medical research

R Williams, M Joffe, A Slonim - 2016 - ideas.repec.org
Health Options Foreclosed: How the FDA Denies Americans the Benefits of Medical Research
IDEAS home Advanced search Economic literature: papers, articles, software, chapters, books …

Drug development and FDA approval, 1938–2013

JJ Darrow, AS Kesselheim - New England Journal of Medicine, 2014 - Mass Medical Soc
This interactive graphic shows major legislative and regulatory events related to approval of
new drugs by the Food and Drug Administration (FDA), drug approvals by year and by …

Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs

M Hottinger, BA Liang - American Journal of Law & Medicine, 2012 - cambridge.org
Generic drugs represent a significant portion of the medical arsenal in treating disease. As
copies of originator drugs, these drugs have been permitted abbreviated approval under the …

[PDF][PDF] Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges

L Knowles, W Luth, T Bubela - Journal of Law and the …, 2017 - academic.oup.com
Personalized medicine (PM) aims to harness a wave of 'omics' discoveries to facilitate
research and discovery of targeted diagnostics and therapies and increase the efficiency of …

[PDF][PDF] Dying for FDA reform

HI Miller, G Conko - CEI On Point, 2007 - cei.org
This year, Congress is considering a variety of legislative changes that would substantially
affect the regulation of pharmaceutical drugs. There is growing momentum for congressional …

Follow-On Biologics: Implementation Challenges and Opportunities

J Paradise - Seton Hall Law Review, 2011 - papers.ssrn.com
Abstract The March 23, 2010, enactment of the Patient Protection and Affordable Care Act
(PPACA) and the companion Health Care and Education Affordability Reconciliation Act of …